ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

The purpose of this study is to evaluate the safety and efficacy of Revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.

Principal Investigator

  • Jared Gollub, MD

CONTACT INFORMATION

Primary Contact:
Alnylam Pharmaceuticals